EFFECT OF ITRACONAZOLE AND TERBINAFINE ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF MIDAZOLAM IN HEALTHY-VOLUNTEERS

被引:77
作者
AHONEN, J
OLKKOLA, KT
NEUVONEN, PJ
机构
[1] UNIV HELSINKI,DEPT CLIN PHARMACOL,SF-00290 HELSINKI,FINLAND
[2] UNIV HELSINKI,CENT HOSP,HELSINKI,FINLAND
关键词
ANTIMYCOTICS; MIDAZOLAM; INTERACTION;
D O I
10.1111/j.1365-2125.1995.tb00001.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Twelve healthy volunteers were given orally placebo, itraconazole 100 mg or terbinafine 250 mg for 4 days. Midazolam 7.5 mg was ingested on the fourth day, after which plasma samples were collected and psychomotor performance tests carried out for 17 h. Itraconazole increased the area under the midazolam concentration-time curve six-fold (P < 0.001), the peak concentration 2.5-fold (P < 0.001) and the elimination half-life two-fold (P < 0.001) compared with placebo and terbinafine pretreatments. The pharmacokinetic parameters did not differ between placebo and terbinafine phases. The higher concentrations of midazolam during the itraconazole phase were associated with increased effects. In contrast to itraconazole, terbinafine had no effect on midazolam pharmacokinetics and psychomotor performance tests were unchanged from placebo.
引用
收藏
页码:270 / 272
页数:3
相关论文
共 10 条
  • [1] DETERMINATION OF ITRACONAZOLE IN SERUM WITH HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY AND FLUORESCENCE DETECTION
    ALLENMARK, S
    EDEBO, A
    LINDGREN, K
    [J]. JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1990, 532 (01): : 203 - 206
  • [2] MIDAZOLAM KINETICS
    ALLONEN, H
    ZIEGLER, G
    KLOTZ, U
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 30 (05) : 653 - 661
  • [3] AZOLES, ALLYLAMINES AND DRUG-METABOLISM
    BACK, DJ
    TJIA, JF
    ABEL, SM
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 1992, 126 : 14 - 18
  • [4] COMPARATIVE EFFECTS OF THE ANTIMYCOTIC DRUGS KETOCONAZOLE, FLUCONAZOLE, ITRACONAZOLE AND TERBINAFINE ON THE METABOLISM OF CYCLOSPORINE BY HUMAN LIVER-MICROSOMES
    BACK, DJ
    TJIA, JF
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 32 (05) : 624 - 626
  • [5] DOSE OF MIDAZOLAM SHOULD BE REDUCED DURING DILTIAZEM AND VERAPAMIL TREATMENTS
    BACKMAN, JT
    OLKKOLA, KT
    ARANKO, K
    HIMBERG, JJ
    NEUVONEN, PJ
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 37 (03) : 221 - 225
  • [6] SIMULTANEOUS DETERMINATION OF MIDAZOLAM AND ITS 3 HYDROXY METABOLITES IN HUMAN-PLASMA BY ELECTRON-CAPTURE GAS-CHROMATOGRAPHY WITHOUT DERIVATIZATION
    DEKROON, IFI
    LANGENDIJK, PNJ
    DEGOEDE, PNFC
    [J]. JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1989, 491 (01): : 107 - 116
  • [7] DOSE-PROPORTIONAL PHARMACOKINETICS OF TERBINAFINE AND ITS N-DEMETHYLATED METABOLITE IN HEALTHY-VOLUNTEERS
    KOVARIK, JM
    KIRKESSELI, S
    HUMBERT, H
    GRASS, P
    KUTZ, K
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 1992, 126 : 8 - 13
  • [8] MIDAZOLAM SHOULD BE AVOIDED IN PATIENTS RECEIVING THE SYSTEMIC ANTIMYCOTICS KETOCONAZOLE OR ITRACONAZOLE
    OLKKOLA, KT
    BACKMAN, JT
    NEUVONEN, PJ
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (05) : 481 - 485
  • [9] ORAL TRIAZOLAM IS POTENTIALLY HAZARDOUS TO PATIENTS RECEIVING SYSTEMIC ANTIMYCOTICS KETOCONAZOLE OR ITRACONAZOLE
    VARHE, A
    OLKKOLA, KT
    NEUVONEN, PJ
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 56 (06) : 601 - 607
  • [10] MIDAZOLAM IS METABOLIZED BY AT LEAST 3 DIFFERENT CYTOCHROME-P450 ENZYMES
    WANDEL, C
    BOCKER, R
    BOHRER, H
    BROWNE, A
    RUGHEIMER, E
    MARTIN, E
    [J]. BRITISH JOURNAL OF ANAESTHESIA, 1994, 73 (05) : 658 - 661